Compare AJANTA PHARMA with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs WOCKHARDT - Comparison Results

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA WOCKHARDT AJANTA PHARMA/
WOCKHARDT
 
P/E (TTM) x 21.6 -18.3 - View Chart
P/BV x 3.8 1.0 394.1% View Chart
Dividend Yield % 0.9 0.0 23,187.6%  

Financials

 AJANTA PHARMA   WOCKHARDT
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
WOCKHARDT
Mar-18
AJANTA PHARMA/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs1,4221,012 140.5%   
Low Rs898532 168.9%   
Sales per share (Unadj.) Rs233.5355.9 65.6%  
Earnings per share (Unadj.) Rs44.0-60.3 -72.9%  
Cash flow per share (Unadj.) Rs52.2-46.8 -111.5%  
Dividends per share (Unadj.) Rs9.000.01 90,000.0%  
Dividend yield (eoy) %0.80 59,890.1%  
Book value per share (Unadj.) Rs255.1257.8 98.9%  
Shares outstanding (eoy) m88.02110.63 79.6%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.02.2 229.0%   
Avg P/E ratio x26.4-12.8 -206.0%  
P/CF ratio (eoy) x22.2-16.5 -134.7%  
Price / Book Value ratio x4.53.0 151.9%  
Dividend payout %20.50 -123,396.2%   
Avg Mkt Cap Rs m102,08185,379 119.6%   
No. of employees `0006.86.3 108.7%   
Total wages/salary Rs m4,3079,371 46.0%   
Avg. sales/employee Rs Th3,022.66,295.0 48.0%   
Avg. wages/employee Rs Th633.41,498.3 42.3%   
Avg. net profit/employee Rs Th569.1-1,066.3 -53.4%   
INCOME DATA
Net Sales Rs m20,55439,369 52.2%  
Other income Rs m2111,202 17.5%   
Total revenues Rs m20,76540,571 51.2%   
Gross profit Rs m5,66418 30,952.5%  
Depreciation Rs m7211,495 48.2%   
Interest Rs m122,555 0.5%   
Profit before tax Rs m5,143-2,830 -181.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m1,273257 495.3%   
Profit after tax Rs m3,870-6,669 -58.0%  
Gross profit margin %27.60 59,287.0%  
Effective tax rate %24.8-9.1 -272.5%   
Net profit margin %18.8-16.9 -111.2%  
BALANCE SHEET DATA
Current assets Rs m11,81233,796 35.0%   
Current liabilities Rs m3,77626,917 14.0%   
Net working cap to sales %39.117.5 223.8%  
Current ratio x3.11.3 249.1%  
Inventory Days Days7779 97.5%  
Debtors Days Days8289 91.4%  
Net fixed assets Rs m14,39839,664 36.3%   
Share capital Rs m175553 31.7%   
"Free" reserves Rs m22,27727,968 79.6%   
Net worth Rs m22,45228,522 78.7%   
Long term debt Rs m721,731 0.0%   
Total assets Rs m26,96281,620 33.0%  
Interest coverage x444.3-0.1 -413,263.4%   
Debt to equity ratio x00.8 0.0%  
Sales to assets ratio x0.80.5 158.0%   
Return on assets %14.4-5.0 -285.6%  
Return on equity %17.2-23.4 -73.7%  
Return on capital %23.0-7.7 -299.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,6829,807 108.9%   
Fx outflow Rs m2,1021,789 117.5%   
Net fx Rs m8,5808,019 107.0%   
CASH FLOW
From Operations Rs m3,748684 547.6%  
From Investments Rs m-2,2286,302 -35.4%  
From Financial Activity Rs m-1,475-7,695 19.2%  
Net Cashflow Rs m45-664 -6.8%  

Share Holding

Indian Promoters % 73.8 74.5 99.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 2.3 67.4%  
FIIs % 7.6 7.7 98.7%  
ADR/GDR % 0.0 0.1 -  
Free float % 17.0 15.4 110.4%  
Shareholders   20,968 67,757 30.9%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   SANOFI INDIA  TORRENT PHARMA  PLETHICO PHARMA  CIPLA  ABBOTT INDIA  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

What Should You Do in Today's Volatile Markets?(Podcast)

The week gone by was pretty volatile for Dalal street and the global environment is as unpredictable as it can get.

Related Views on News

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Small Cap Stocks Could Triple in Less than 2 Years... Here's Why(Profit Hunter)

Sep 30, 2019

Historical data backs up my conviction.

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Interest Rates Are Low. Buy Solid Dividend Stocks Instead(The 5 Minute Wrapup)

Sep 30, 2019

Select dividend stocks can be very rewarding.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Oct 11, 2019 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS